Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q4 FY21 results · Jan–Mar 2021
Solara Active Pharma Sciences reported revenue from operations of ₹444.21 crore (up 49.7% from Q4 FY20) and net profit of ₹56.61 crore (up 217.9% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 444.21 | 296.77 | +49.7% | 426.69 | +4.1% |
| Other income | 9.78 | 12.13 | −19.4% | 8.29 | +18.0% |
| Total income | 453.99 | 308.90 | +47.0% | 434.98 | +4.4% |
| Profit before tax | 56.62 | 17.90 | +216.3% | 65.79 | −13.9% |
| Net profit for the period | 56.61 | 17.81 | +217.9% | 65.78 | −13.9% |
| Attributable to shareholders of the company | 56.65 | 14.26 | +297.3% | — | — |
| EPS, basic (₹) | 15.57 | 6.78 | +129.6% | 18.47 | −15.7% |
| Net margin (%) | 12.7 | 6.0 | 15.4 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 444.21 | 296.77 | +49.7% | 426.69 | +4.1% |
| Other income | 9.86 | 12.11 | −18.6% | 8.29 | +18.9% |
| Total income | 454.07 | 308.88 | +47.0% | 434.98 | +4.4% |
| Profit before tax | 57.15 | 18.18 | +214.4% | 65.78 | −13.1% |
| Net profit for the period | 57.15 | 18.18 | +214.4% | 65.78 | −13.1% |
| EPS, basic (₹) | 15.47 | 6.92 | +123.7% | 18.48 | −16.3% |
| Net margin (%) | 12.9 | 6.1 | 15.4 |
Consolidated
- Filed with BSE
- 07 May 2021, 15:18 IST
- Board meeting
- 06 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 May 2021, 15:18 IST
- Board meeting
- 06 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE